Annual Drug Patent Expirations for LENVIMA
Lenvima is a drug marketed by Eisai Inc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for LENVIMA.
This drug has one hundred and twenty-four patent family members in thirty-five countries.
The generic ingredient in LENVIMA is lenvatinib mesylate. Additional details are available on the lenvatinib mesylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
